Podcasts about Structural biology

In this episode of Crazy Wisdom, Stewart Alsop speaks with German Jurado about the strange loop between computation and biology, the emergence of reasoning in AI models, and what it means to "stand on the shoulders" of evolutionary systems. They talk about CRISPR not just as a gene-editing tool, but as a memory architecture encoded in bacterial immunity; they question whether LLMs are reasoning or just mimicking it; and they explore how scientists navigate the unknown with a kind of embodied intuition. For more about German's work, you can connect with him through email at germanjurado7@gmail.com.Check out this GPT we trained on the conversation!Timestamps00:00 - Stewart introduces German Jurado and opens with a reflection on how biology intersects with multiple disciplines—physics, chemistry, computation.05:00 - They explore the nature of life's interaction with matter, touching on how biology is about the interface between organic systems and the material world.10:00 - German explains how bioinformatics emerged to handle the complexity of modern biology, especially in genomics, and how it spans structural biology, systems biology, and more.15:00 - Introduction of AI into the scientific process—how models are being used in drug discovery and to represent biological processes with increasing fidelity.20:00 - Stewart and German talk about using LLMs like GPT to read and interpret dense scientific literature, changing the pace and style of research.25:00 - The conversation turns to societal implications—how these tools might influence institutions, and the decentralization of expertise.30:00 - Competitive dynamics between AI labs, the scaling of context windows, and speculation on where the frontier is heading.35:00 - Stewart reflects on English as the dominant language of science and the implications for access and translation of knowledge.40:00 - Historical thread: they discuss the Republic of Letters, how the structure of knowledge-sharing has evolved, and what AI might do to that structure.45:00 - Wrap-up thoughts on reasoning, intuition, and the idea of scientists as co-evolving participants in both natural and artificial systems.50:00 - Final reflections and thank-yous, German shares where to find more of his thinking, and Stewart closes the loop on the conversation.Key InsightsCRISPR as a memory system – Rather than viewing CRISPR solely as a gene-editing tool, German Jurado frames it as a memory architecture—an evolved mechanism through which bacteria store fragments of viral DNA as a kind of immune memory. This perspective shifts CRISPR into a broader conceptual space, where memory is not just cognitive but deeply biological.AI models as pattern recognizers, not yet reasoners – While large language models can mimic reasoning impressively, Jurado suggests they primarily excel at statistical pattern matching. The distinction between reasoning and simulation becomes central, raising the question: are these systems truly thinking, or just very good at appearing to?The loop between computation and biology – One of the core themes is the strange feedback loop where biology inspires computational models (like neural networks), and those models in turn are used to probe and understand biological systems. It's a recursive relationship that's accelerating scientific insight but also complicating our definitions of intelligence and understanding.Scientific discovery as embodied and intuitive – Jurado highlights that real science often begins in the gut, in a kind of embodied intuition before it becomes formalized. This challenges the myth of science as purely rational or step-by-step and instead suggests that hunches, sensory experience, and emotional resonance play a crucial role.Proteins as computational objects – Proteins aren't just biochemical entities—they're shaped by information. Their structure, function, and folding dynamics can be seen as computations, and tools like AlphaFold are beginning to unpack that informational complexity in ways that blur the line between physics and code.Human alignment is messier than AI alignment – While AI alignment gets a lot of attention, Jurado points out that human alignment—between scientists, institutions, and across cultures—is historically chaotic. This reframes the AI alignment debate in a broader evolutionary and historical context, questioning whether we're holding machines to stricter standards than ourselves.Standing on the shoulders of evolutionary processes – Evolution is not just a backdrop but an active epistemic force. Jurado sees scientists as participants in a much older system of experimentation and iteration—evolution itself. In this view, we're not just designing models; we're being shaped by them, in a co-evolution of tools and understanding.

In our first episode of 2025, our hosts, Chris Williams and Dave Thompson, have the pleasure of speaking to Fernando Garces, CEO and co-founder of BioGlyph. Leading us from the sunny climes of Portugal through the tropical paradise that is London, on route to the West Coast of the US and A, Fernando shares his evolving love of science through the heights of academia, into industry, and now as CEO of a software company he co-founded to improve the modeling of complex multispecifics. Important questions are unpacked throughout - is London really a tropical paradise? How long can we keep milking podcast episode titles that take advantage of the homophonic property of pharma and farm? Oh, and we have another surprising guest answer to the ‘Deschênes Dilemma'… It is not to quote G. K. Chesterton, a proper nailbiter!

Race Oncology Ltd (ASX: RAC, OTC: RAONF) executive chair Dr Peter Smith joins Proactive's Tylah Tully to discuss the latest updates at the company. It has completed a board renewal process, marking a significant milestone as the company prepares for its next phase of development. The company expressed gratitude to non-executive chair Mary Harney and non-executive director and former CEO/MD Phil Lynch for their four years of service. As part of the renewal, Dr Smith has been appointed as the executive chair, while Dr Daniel Tillett, the current CEO, will also take on the role of managing director. Additionally, Dr Serge Scrofani has joined the board as an independent non-executive director, bringing more than 28 years of experience in the healthcare sector, including key strategic roles at CSL. Dr Scrofani's extensive experience in research, strategy and corporate development, particularly in driving strategic initiatives and executing major mergers and acquisitions, is expected to play a pivotal role in Race Oncology's future. Currently, Dr Scrofani is the principal of Poplar Advisory and he serves on the boards of the Burnet Institute and The Centre for Eye Research. He also holds a PhD in Structural Biology and an MBA from Melbourne Business School. #Proactiveinvestors #RaceOncology #ASX #BoardRenewal, #HealthcareLeadership, #Bisantrene, #CancerTherapies, #ASXNews, #CorporateDevelopment, #StrategicLeadership, #Pharmaceuticals, #HealthcareSector, #BiotechNews, #ExecutiveAppointments, #MedicalResearch, #CorporateStrategy, #HealthcareInnovation #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

In this episode of The Chain, host Brandon DeKosky, associate professor at MIT, speaks with Andrew Kruse, PhD, professor of biological chemistry and molecular pharmacology at Harvard University, about protein signaling and structural biology. Kruse explains what exactly bias signaling is and discusses the problems he and his team are working to resolve, as well as the tools they use to work out the dynamics of structures. He also shares the findings in signaling receptors and biology that he's most excited about, recent advancements that have caught his attention, and the new directions for him and his lab.  

It's time for another trip around the solar system on the BIGGER and BETTER Science Weekly!  This episode of the Fun Kids Science Weekly we continue our bigger and better podcast where we put YOUR questions to our team of experts, have scientists battle it out for which science is the best & learn all about the discovery of the earliest and most distant galaxy. Dan starts with the latest science news, where we learn about a rare bridled tern and a golden puffin discovered just off the North East coast of the UK, how firefighters are dealing with wildfires in the world's biggest tropical wetlands in Brazil - The Pantanel and Kevin Hainline from the University of Arizona tells us about the earliest and most distant galaxy discovered by the James Webb Telescope called JADES-GS-z14-0. Then we delve into your questions where Dan explains how viruses are cured and we pose Tiffany's question on how the northern lights are formed to Astronomer Tom Kerss. Dangerous Dan continues and we learn all about the Goliath Tiger Fish and why it's so feared in African waters.The Battle of the Sciences continues where Dan chats to Charlotte Dodson from the University of Bath about why Structural Biology is the best kind of science? What do we learn about? - Two rare fish discovered off the coast of the UK - Brazil's Tropical Wildfires - The most distant and earliest galaxy discovered by the James Webb Telescope - How the Northern Lights are formed? - Is Structural Biology the best type of science? All on this week's episode of Science Weekly!Join Fun Kids Podcasts+: https://funkidslive.com/plusSee omnystudio.com/listener for privacy information.

Dr. Daniel Stone speaks with Drs. Mario Mietzsch and Robert McKenna from the University of Florida to discuss a recent article published in the Biomanufacturing in Gene and Cell Therapy special issue of Molecular Therapy Methods & Clinical Development by Drs. Mietzsch, McKenna, and colleagues titled Production and characterization of an AAV1-VP3-only capsid: An analytical benchmark standard. If you enjoy today's conversation, you'll also enjoy the upcoming ASGCT Policy Summit in Washington, DC, September 23-24.  This can't-miss event brings together policymakers and gene and cell therapy experts, including FDA leaders Julie Tierney and Dr. Nicole Verdun, to discuss the latest policies impacting this rapidly evolving field.  Register now at https://www.asgct.org/PolicySummit for invaluable insights on navigating the regulatory landscape.  In This Episode: Dr. Daniel StoneAssociate Editor-in-Chief of Molecular Therapy Methods & Clinical Development and Senior Staff Scientist, Infectious Disease Sciences, Vaccine and Infectious Disease Division at Fred Hutch Cancer Center Dr. Mario MietzschAssistant Scientist, Department of Biochemistry and Molecular Biology, University of Florida Dr. Robert McKennaProfessor and Director of the Center for Structural Biology, Department of Biochemistry and Molecular Biology, University of Florida 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Roderick MacKinnon won the 1999 Lasker Award for elucidating the structure of potassium channels. His work provided the first molecular description of an ion selective channel and helped knock down what he called “psychological barriers” in the field. After MacKinnon, the structure of transmembrane ion channels went from being seen as unsolvable to solvable. In this 1999 interview with Chris Miller, Professor of Biochemistry at Brandeis University, MacKinnon shares anecdotes from his early career, discusses how the field reacted to his groundbreaking work, and talks about what motivates him scientifically. This interview has been edited for clarity and brevity. Find the full 55-minute interview here: https://laskerfoundation.org/winners/function-and-structure-of-ion-channels/  

Episode 85. Fay Lin is a Senior Editor at GEN Biotechnology. She completed her PhD in Biochemistry, Molecular, and Structural Biology at UCLA and undergrad in Biology at NYU with minors in Computer Science and Chemistry.GEN Biotechnology website: https://home.liebertpub.com/genbioCall for Papers: Special Issue in AI in Biotechnology: https://home.liebertpub.com/cfp/special-issue-artificial-intelligence-in-biotechnology/497/

Du kender helt sikkert Johan Olsen som forsanger i Magtens Korridorer, hertil spiller han teater, arbejder som radiovært, og han har også udgivet flere bøger. Men som om det ikke var nok, så er Johan Olsen også forsker. Nærmere bestemt er han ansat som adjunkt på Biomolecular Science ved afdelingen Structural Biology and NMR Laboratory ved Københavns Universitet. Men hvad er det egentligt hele Danmarks Johan Olsen forsker i, når han ikke underholder på scenen eller formidler sin viden og tanker i radiostudiet og gennem sine bøger? Hvordan skruer han en hverdag sammen, hvor han kan have så mange forskellige hatte på? Og hvad er det fedeste ved at være både musikstjerne og kæmpe biologi-nørd? Medvirkende: Johan Olsen. Værter: Peter Løhde & Andrew Davidson.See omnystudio.com/listener for privacy information.

Caezar Al-Jassar is the director at Alley Cat Games and heads of product development and business strategy. He originally started out as a postdoctoral academic working at British universities and institutions such as Birmingham University, UCL and the LMB with multiple first author papers in the field known as “Structural Biology”. He started Alley Cat Games, which he co-founded with his wife, back in 2016 with the successful Kickstarter campaign for their inaugural game: Lab Wars. With over 80 skus since then and games in high street stores such as Barnes and Noble and Waterstones, Caezar likes to ensure that everything they do is of the highest quality bursting with theme and fun. Alley Cat Games features games that are mass market friendly all the way up to complex hobby games so they're always something in their line compatible with any type of gamer!You can learn more about Alley Cat Games at alleycatgames.comFOLLOW US ON: Facebook: https://www.facebook.com/groups/boardgamebingeInstagram: https://www.instagram.com/boardgamebingepodcast/ Twitter: https://www.twitter.com/boardgamebingeWHERE TO FIND OUR PODCAST:Spotify: https://open.spotify.com/show/5RJbdkguebb3MSLAatZr7riHeart Radio: https://www.iheart.com/podcast/269-board-game-binge-72500104/Tune In: https://tunein.com/embed/player/p1344218/Google Podcasts: https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5jYXB0aXZhdGUuZm0vYm9hcmRnYW1lYmluZ2U=Apple Podcasts: https://podcasts.apple.com/ca/podcast/board-game-binge/id1522623033Visit Our Websites: Board Game Binge: https://boardgamebinge.com/Tin Robot Games: https://tinrobotgames.comElixir Board Games: https://www.elixirboardgames.com/our-gamesBoard Game Design Course: https://boardgamedesigncourse.com/

This podcast format is inspired by the Charles Dicken's novella “A Christmas Carol” whereby Phil Jeffrey (Bicycle Therapeutics), Beth Williamson (UCB) and Daniel Price (Nimbus) discuss DMPK Past, Present and Future with Scott.  Key elements discussed include the evolution of DMPK as a predictive discipline that links helps the chemistry of drug design with the biology of drug disposition and effect.The episode addresses the following questions:The founding names and principles of DMPK and the emergence of Discovery DMPKToday's use of technologies and in silico modelling and DMPK's role in the 3 pillars/5Rs and PK/PD The outlook for better prediction with advances in AI/MLSpeakers:Phil Jeffrey - Senior Vice President of Preclinical Development at Bicycle TherapeuticsPhil Jeffrey is now semi-retired after contributing to DMPK for over 35 years in the pharmaceutical industry.  Most recently, Phil was Senior Vice President of Preclinical Development at Bicycle Therapeutics and previously has held positions at Pfizer, GlaxoSmithKline, SmithKline Beecham and The Upjohn Company.  Phil is a longstanding contributor the Society for Medicines Research and is an Honorary Professor at the William Harvey Research Institute, Queen Mary University of London.  Phil has a wide breadth of experience across DMPK from, Drug Discovery and early lead optimisation through to clinical proof of mechanism and proof of concept across a wide variety therapeutic areas and drug modalities and made significant contributions to the advancement of understanding the CNS penetration of drugs into the brain. Beth Williamson - Head of ADME in the DMPK group at UCBBeth graduated with a PhD in Pharmacology from the University of Liverpool and is now Head of ADME in the DMPK group at UCB where she also represents DMPK on projects throughout discovery and development. Beth's work has focussed on in vitro and in vivo ADME assay optimisation and validation within drug discovery, particularly to address bespoke questions. Beth has worked in the fields of oncology, neurology and immunology. Her main research interests include drug-drug interactions, extrapolation of pre-clinical in vitro and in vivo data for the prediction of human pharmacokinetics and application of AI/ML approaches within DMPK.  Daniel Price - Vice President of Computational Chemistry & Structural Biology at Nimbus TherapeuticsDr. Daniel Price is Vice President of Computational Chemistry & Structural Biology at Nimbus Therapeutics, where he leads a team of internal and external scientists focused on delivering breakthrough medicines through structure-based design, leveraging both physics-based and knowledge-based predictive modeling.  Before joining Nimbus, he spent 16 years at GlaxoSmithKline, where he led a team of computational chemists and data scientists across diverse areas of structure- and ligand-based drug design, high-content screening analytics, predictive ADME, predictive synthesis, and chemogenomics.  He has led drug discovery programs, contributed to 4 clinical candidates, led the development of GSK's first generation R&D data lake, and authored/co-authored 26 publications.  Dr. Price received his undergraduate degree in chemical engineering from University of Colorado at Boulder followed by his Ph.D. in Molecular Biophysics & Biochemistry from Yale University with Prof. Bill Jorgensen.   He completed an NIH postdoctoral fellowship with Prof. Charlie Brooks, III at The Scripps Research Institute prior to joining GSK. Stay tuned for more podcasts in our Pharmaron DMPK Insights Series!

Ion channel block unraveled Transcript of this podcastHello and welcome to the NanoLSI podcast. Thank you for joining us today. In this episode we feature the latest research by Takashi Sumikama at the Kanazawa University NanoLSI in collaboration with Katsumasa Irie from Wakayama Medical University and colleagues.The research described in this podcast was published in Nature Communications in July 2023 Kanazawa University NanoLSI websitehttps://nanolsi.kanazawa-u.ac.jp/en/Ion channel block unraveledResearchers at Kanazawa University report in Nature Communications how calcium ions can block sodium ion channels located in cell membranes. Structural analysis and computer simulations made it possible to identify where and why calcium ions get stuck. Ion channels are structures within cell membranes that enable specific ions to travel to and from the cell. Such transfer is essential for a variety of physiological processes like muscle cell contraction and nerve excitation. In so-called tetrameric cation channels, the ion selectivity results from the unique structural and chemical environment of the part referred to as the selectivity filter, which is located between two intertwined helical structures. Tetrameric ion channels are prone to ‘divalent cation block', the blocking of the channel by ions like calcium (as in Ca2+). Such blocking regulates the ionic current, which is involved in various neural activities such as memory formation. How divalent cation block happens exactly is still unclear at the moment — in particular, a direct observation of the cation actually blocking the ion pathway has not been reported yet. Now, Takashi Sumikama from Kanazawa University in collaboration with Katsumasa Irie from Wakayama Medical University and colleagues has discovered the mechanism behind divalent cation block in NavAb, a well-known tetrameric sodium (Na) channel. Through structural analysis and computer simulations, the researchers were able to reveal the relevant structural features and molecular processes at play.So how did they go about this structural analysis?NavAb is a sodium channel cloned from a bacterium (Arcobacter butzleri) and has a well-known structure. Sumikama and Irie's colleagues performed experiments with NavAb and three mutants. The structures of the mutants were determined for environments with and without calcium. The scientists focused on the differences in electron densities for the different structures, as these provide insights into the locations of the calcium ions. They found that for the mutants displaying calcium blocking, one or two calcium ions are located at the bottom of the selectivity filter. They also discovered that two other divalent cations — magnesium (as in Mg2+) and strontium (Sr2+) ions — blocked the calcium-blocking mutant sodium channels.The researchers then performed computer simulations to obtain a detailed understanding of the interaction between the calcium ions and the mutated NavAb channels. The simulations reproduce the dynamics of ions passing — or not passing — the channel. In the absence of calcium ions, sodium ions were observed to penetrate the channel. In the presence of calcium ions, penetration significantly decreased in the calcium-blocking mutants. The simulations also confirmed that the blocking calcium ions are ‘stuck' at the bottom of the selectivity filter, and revealed that this ‘sticking' is related to the increased hydrophilicity (affinity to water) of relevant structural parts of the mutated channels.The results of Sumikama and Irie's colleagues provide an important step forward towards a full understanding of the mechanism of divalent cation block in NavAb, an important and representaNanoLSI Podcast website

Today I am speaking with Dr. Amy Kruse.She is a neuroscientist, General Partner, and Chief Investment Officer at Satori Neuro, a venture capital fund focused on mental health, neurotechnology, and human flourishing.Amy earned a Bachelor of Science in Cell and Structural Biology and a Ph.D. in Neuroscience from the University of Illinois at Champaign-Urbana. She went on to serve as a program manager at the Defense Advanced Research Projects Agency (DARPA), where she oversaw the agency's first performance-oriented neuroscience programs and orchestrated scientific breakthroughs in augmented cognition, accelerated learning, optimized imagery analysis, team neurodynamics, and neuromodulation.After DARPA, she served as the Vice President and Chief Technology Officer of Cubic Global Defense and Chief Scientific Officer of Optios.Prior to joining Satori Neuro, Dr. Kruse was a General Partner at Prime Movers Lab, where she led the fund's life sciences investments in human augmentation and longevity.In this episode, we talk about:* The neuroscience of learning;* How to improve human performance and mastery;* The connection between meditation and psychedelic research; and* The varieties of neurotechnology.Listen to the episode on Substack, Spotify, Google, or Apple.Credits:* Hosted by Zach Haigney * Produced by Zach Haigney, Erin Greenhouse, and Katelin Jabbari* Find us at thetripreport.com* Follow us on Instagram, Twitter, LinkedIn and YouTube* Theme music by MANCHO Sounds, Mixed and Mastered by Rollin Weary This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thetripreport.com

Kanazawa Univesity NanoLSI Podcast:Dynamic 3D structure extraction from HS-AFM imagesTranscript of this podcast Hello and welcome to the NanoLSI podcast. Thank you for joining us today. In this episode we feature the latest research by  Holger Flechsig and Toshio Ando at the Kanazawa University NanoLSI. The research described in this podcast was published in the journal Current Opinion in Structural Biology in April 2023 Kanazawa University NanoLSI website  https://nanolsi.kanazawa-u.ac.jp/en/ Dynamic 3D structure extraction from high-speed atomic force microscopy images  By allowing the direct observation of biomolecules in dynamic action, high-speed atomic force microscopy or AFM has opened a new avenue to dynamic structural biology. A vast number of successful applications within the past 15 years have provided unique insights into essential biological processes at the nanoscale – visualizing, for example, how molecular motors execute their specific functions. Some intrinsic limitations of AFM imaging are that only the surface topography can be acquired, and that the AFM tip is too large to resolve details below the nanometer scale. To facilitate the interpretation and understanding of high-speed AFM observations, post-experimental analysis and computational methods play an increasingly important role. In their review paper published in the Current Opinion in Structural Biology journal Holger Flechsig a computational scientist at the NanoLSI at Kanazawa University and Toshio Ando, a Distinguished Professor at NanoLSI, provide an overview of developments in this topical field of interdisciplinary research. Computational modeling and simulations already allow the reconstruction of 3D conformations with atomistic resolution from topographic resolution-limited AFM images. Furthermore, quantitative analysis methods allow for example automated recognition of biomolecular shape changes from topographic images, or feature assignment including the identification of amino acid residues on the molecular surface.So how is all this implemented?The developed computational methods are often implemented in open-access software, allowing for convenient applications by the broad Bio-AFM community to complement experimental observations. In that regard, the BioAFMviewer software project initiated at Kanazawa University in 2020 has gained significant attention and plays an important role in a plethora of collaboration projects.Combining high-speed AFM and computational modeling will elevate the understanding of how proteins function in atomistic detail. An ambitious future goal is the application of molecular modeling to reconstruct atomistic-level 3D molecular movies from high-speed AFM topographic movies.ReferenceHolger Flechsig and Toshio Ando. Protein dynamics by the combination of high-speed AFM and computational modelingNanoLSI Podcast website

This talk explores the fascinating world of crystals and their role in biology and medicine. Crystals have always been admired for their beauty and value, and many believe they have powerful, magic properties. They play critical roles in various biological processes, such as supporting bones, grinding food, protecting shells, and more. However, crystals can also lead to diseases like kidney stones, atherosclerosis, and gout. The speaker will explain the study of crystal formation, assembly, and their impact on health and disease. Speakers Lia Addadi, Professor of Structural Biology, The Weizmann Institute of Science

There have been a lot of stories in the news over the last few months about AI chatbots like ChatGPT that can respond to your questions with convincing and well-written answers. These so-called large language models can tell you how to build a treehouse, how to bake a cake, or how to sleep better. But notice that word large. Behind the scenes, these models have learned which word tend to cluster together by sifting through hundreds of billions of pieces of data—basically the entire Internet, in the cast of ChatGPT, including all of Wikipedia and thousands of published books. Now imagine that another chatbot came along that could learn how to generate convincing text response by studying only, say, 18 sentences. Something like that is what this week's guest Raphael Townshend, the founder and CEO of Atomic AI, has accomplished when it comes to predicting the structure of RNA molecules.RNA has been in the news a lot lately too. That's in part because some of the vaccines that helped us beat back the coronavirus pandemic were made from messenger RNA, a form of the molecule that instructs cells how to build proteins (in that case, antibodies to the virus). But RNA has many other functions in the body, and if we knew how to design small-molecule drugs to attach to binding pockets on any given RNA to interrupt or modulate its functions, it could open up a whole new realm of medical treatments. The problem is, if all you know about an RNA molecule is its nucleotide sequence, it's very hard to predict where those binding pockets might be and what kind of drug might fit into them. As a PhD student at Stanford, Townshend designed a deep learning model to tackle that problem. The model, called ARES, started with a proposed structure for an RNA molecule with a known nucleotide sequence, and predict how that proposal would compare to real-world data. ARES turned out to be stunningly accurate, and it acquired its skills by studying a remarkably small training set: just 18 examples of RNAs with known structures. So in a way, it was using the power of small data, together with a bit of physics. Now Atomic AI is building on that original model to create an engine for discovering new small-molecule drugs that could potentially interrupt any disease where RNA is a player.For a full transcript of this episode, please visit our episode page at http://www.glorikian.com/podcast Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:1. Open the Podcasts app on your iPhone, iPad, or Mac. 2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.3. Scroll down to find the subhead titled "Ratings & Reviews."4. Under one of the highlighted reviews, select "Write a Review."5. Next, select a star rating at the top — you have the option of choosing between one and five stars. 6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.7. Once you've finished, select "Send" or "Save" in the top-right corner. 8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out. 9. After selecting a nickname, tap OK. Your review may not be immediately visible.That's it! Thanks so much.

Dr. Hao Wu is the Asa and Patricia Springer Professor of Structural Biology at Harvard Medical School. Her lab focuses on the molecular and cellular mechanisms that govern the assembly, regulation, and therapeutic intervention of supramolecular complexes in innate immunity. She talks about cryo-electron microscopy and how her team used it to study the structures of the NLRP3 inflammasome disc, the B cell antigen receptor, and the Gasdermin D pore. She also discusses the role of AlphaFold in structural biology research.

Over the last two decades, cryogenic electron microscopy (cryo-EM) has transformed from what Dr. Andrew Ward calls the “outcast of structural biology” to one of the most promising technologies in the field. Ward, professor of integrative structural and computational biology at Scripps Research Institute, speaks with moderator Brandon DeKosky, assistant professor of chemical engineering at the Massachusetts Institute of Technology, about the evolution of cryo-EM and how its direct detector transformative technology enables scientists to craft favorable antibody responses. Ward also talks about cryo-EM's technological advantages when working with proteins, sterilizing immunity, and designing accurate structural biology pipelines that lead to next-generation vaccines. Finally, Ward offers his predictions about the immunological breakthroughs he thinks structural biologists will accomplish in the very near future.  Links from this episode:  Scripps Research Institute PepTalk Conference Discovery on Target Conference 

Episode 65. Tari Suprapto is a Director of Search and Evaluation at Novo Nordisk and Board Chair at the San Diego Innovation Council. Tari completed her PhD at The Rockefeller University in Cellular and Structural Biology and has worked in technology transfer and business development at The Rockefeller University and Salk Institute.

In this month's episode of the Psychedelics in Medicine Podcast (PiMPOD), Dr Torsten Passie and Ben Clayden discuss LSD Derivatives, A nearly identical molecule with just a few differences. We discuss multiple derivatives of LSD, including LSA, 2-Bromo-LSD (BOL-148), 1P-LSD and use them in combination to better understand the intricacies of the neural mechanisms of LSD, and how slight changes to a molecules three-dimensional structure can completely alter their effects, through differences in ligand-receptor binding.We then look at a study using a non-hallucinogenic version of LSD, BOL-148 as preventative treatment for cluster headache, discussing its implications, and further research that could be completed relating to LSD derivatives.Dr Passie is a German psychiatrist, professor at Hannover Medical School and is an expert in altered states of consciousness. Torsten has performed clinical and experimental studies numerous psychoactive and psychedelic compounds ranging from nitrous oxide, to MDMA to ketamine.Ben Clayden is the creator and owner of this Podcast. He is a student at the University of York studying Natural Sciences specialising in Neuroscience. He is co-chair for the Drug Science Student Society Network as well as the president of his University's Psychedelics in Medicine Society.Psychedelics, LSD, Hallucinogens Biology, Chemistry, Structural Biology, Neuroscience Cluster Headaches,Useful LinksINSTAGRAM - https://www.instagram.com/psymedpod/LINKTREE - https://linktr.ee/psymedpodRSS - https://rss.com/podcasts/psymedpod/ReferencesKarst M, Halpern JH, Bernateck M, Passie T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia. 2010 Sep;30(9):1140-4. doi: 10.1177/0333102410363490. Epub 2010 Mar 26. PMID: 20713566.

Winds of change are howling in Germany, with the draft healthcare bill now approved to stabilise SHI fund finances. What will manufacturers, with innovative orphan drugs and cell and gene therapies, launch strategies be? With the latest decision from Janssen to avoid the German market altogether for x2 Rare Oncology innovative drugs, will this be a trend we are likely to see continue? Join Stefan Walzer & Fisentzos Stylianou discuss the new bill, in regards to the biggest changes that impact orphan drug (OD) manufacturers. Will OD manufacturers still see Germany as the first go to market within Europe and what does this means for rare disease patients? Will there be delays to new treatments or will manufacturers decide not to launch in Germany at all to protect the price of their new drug? We will be discussing this and so much more! If you are a drug manufacturer planning your launch strategy, this podcast is for you! Presenters: Georgie Rack & Owen Bryant Guests Stefan Walzer, CEO President & Founder of MArS Market Access & Pricing Strategy GmbH Fisentzos Stylianou, senior analyst and P4A's German country expert Dr Stefan Walzer, CEO President & Founder at MArS Market Access &Pricing Strategy GmbH https://marketaccess-pricingstrategy.de/en/ Bio & Fun Facts 1) Economist, PhD in health economics, diploma in clinical trials 2) Experience in MA, reimbursement, HE and pricing since 2004 in consultancy and industry 3) Founder and CEO of MArS - THE D-A-CH market access consultancy. Linked to that also co-founder of SMS2DACH including the full spectrum for D-A-CH support (distribution, management, launch, etc.): www.sms2dach.com 4) Founder of P&N (pricing-and-negotiations.ca) with a focus on negotiations across the world including being the co-founder of www.thenegotiationlab.com 5) Member of a European network Tesseract (https://www.tesseracteurope.com/) which can serve companies moving from outside Europe into Europe including not only reimbursement services but also logistics, customs, etc. 6) Teaching at various German universities 7) Love spending time with my family, being a soccer coach of under 14 years-old and being a supporter of Borussia Dortmund Fisentzos Stylianou, Senior Analyst & German Country Expert Fisentzos role at Partners4Access includes conducting primary and secondary research to support the development of market access and reimbursement strategies for clients in the pharmaceutical and biotechnology industries. With a passion for innovative treatments, he closely follows the cell and gene therapy field as it expands to treat more patients with rare diseases. Prior to joining Partners4Access, Fisentzos worked as a Research Associate at Imperial College London, where he also earned his Ph.D. in Structural Biology in 2020. During this time, he conducted research as part of a multidisciplinary team to advance his understanding of the structure and function of biofilm-forming proteins, paving the way for the design of novel antimicrobial therapeutics. Fisentzos also holds an M.Sc. in Biomedical and Molecular Sciences Research and a B.Sc. in Biomedical Science, both from King's College London.

ABOUT TODAY's EPISODE Is your hair stuck at a particular length for long periods, or worse, do you have regression in your hair growth? Are you using all the "how to grow hair fast methods" and yet, you somehow fall short. If so, you want to pay close attention to today's episode where I highlight hair structure focusing on African hair structure and how it ties to hair porosity and cuticle preservation. SUPPORT! Thank you SO much for your constant support. It means the world to me. If you are wondering how you can support, please see below Share share share to the ends of the world: You can share this podcast to as many people as you know and love. You does not love a fun podcast about hair and skin? See links for that here https://linktr.ee/ChiomaAgha Support financially: https://anchor.fm/chioma-agha Download: Do you know that you can download any episode? Take me (well my voice, LOL) anywhere you are. Just click on download, and voila! Listen: Errmmm listen listen and listen again. You can listen one zillion uncountable billion times. LOL. Listen to the Ads ooooooo. T for Tenks REFERENCES 1. Hessefort, Yin et al. “True porosity measurement of hair: a new way to study hair damage mechanisms.” Journal of cosmetic science vol. 59,4 (2008): 303-15. 2. Sandra L. Koch, Mark D. Shriver, Nina G. Jablonski. Variation in human hair ultrastructure among three biogeographic populations. Journal of Structural Biology, Volume 205, Issue 1, 2019, Pages 60-66, ISSN 1047-8477. Disclaimer The information provided on this podcast, including but not limited to, text, graphics, are for informational purposes only and does not serve as a diagnosis, treatment or substitute for medical advice. Always seek the advice of a qualified health care professional for any medical condition you may be experiencing. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/chioma-agha/support

 we're joined by Dr. Andrey Kovalevsky, Senior Scientist in Structural Biology & Biochemistry at Oak Ridge National Laboratory. Andrey and his team used neutrons and x-rays to map part of the internal structure of the coronavirus to create an accurate 3-D model. Specifically, the scientists mapped the main protease (Mpro), an enzyme involved in the virus replication, to which they had added a preliminary small molecule discovered using high-speed computer screening and virtual reality (VR). Using the MedChem tool in Nanome to look at the enzyme model, the scientists virtually constructed different small molecules by modifying their structures to see if any newly designed compounds could fit, or bind, to a key site on the Mpro enzyme surface. A strong enough binding could inhibit, or block, the enzyme from functioning, which is vital to stopping the virus from multiplying in patients with COVID-19. References: Kneller et al. (2021). Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease. J. Med. Chem. 64, 8, 4991–5000. DOI: 10.1021/acs.jmedchem.1c01475 https://neutrons.ornl.gov/content/jou...https://www.pfizer.com/news/press-rel...https://www.rcsb.org/structure/7SI9

On Episode 31 of Black in Science, I sat down with Dr. Jamaine Davis who currently works as an Assistant Professor in the Department of Biochemistry and Cancer Biology at Meharry Medical College. To open, Dr. Davis discusses his childhood while growing up in Long Island, New York. He then segues into his experience as an undergraduate chemical engineering major at Temple University and Drexel University in Philadelphia, Pennsylvania before discussing his transition into the biomedical research field. After sharing the details of his Ph.D dissertation research in the Department of Biochemistry and Molecular Biophysics at the University of Pennsylvania, Dr. Davis delves into the work he did for both of his postdoctoral fellowships at the National Cancer Institute in Maryland. Following this, Dr. Davis describes the Breast cancer and Alzheimer's structural biology and health disparities research his lab focuses on before disclosing his short term and long term goals. To conclude, Dr. Davis shares his feelings on the importance of seeking help, remaining your authentic self and more. If you've enjoyed listening to Dr. Davis' episode of the podcast and wish to contact him with questions, feel free to reach out via: Email: jdavis@mmc.edu Twitter: @jscdavis

東大先進科学機構の加藤英明さん(@emeKato)をゲストに、今回のChRmine構造論文やこれまでの仕事の背景、神経科学者が構造生物学について知っておくと良いこと、今後の構造生物学の展開等を伺いました。(2/20収録) Show Notes(完全版は番組HP): 加藤研 加藤さん過去インタビュー 1 2 ChRmineの論文 濡木研 Brian Kobilkaラボ Brianノーベル賞のページ 2012年のNature論文（ChR1とChR2のキメラ、C1C2の構造解析） の新着論文レビュー 服部素之さん タンパク質結晶化の基礎と蒸気拡散法の解説 (pdf注意) 芳賀先生のNature 2012 （註：だいぶ年が間違ってましたね・・・ by 加藤さん） 脂質キュービックフェーズ（LCP）法 （pdf注意） Nanobodyを使ったBrianたちの論文 iC++の構造論文（Nature筆頭論文その３） GtACR1の構造論文（Nature筆頭論文その４） 上記論文の新着論文レビュー 微生物型ロドプシンの作動メカニズムについての神取先生の解説記事 加藤先生のアドバンスト理科 Kalium rhodopsins クライオ電顕の原理の解説（吉川研） David Juliusが取ってた NTSR1-Gi1のCanonical と Non Canonicalクライオ構造論文（N筆頭その５） AlphaFold2論文 死の脳内表象について(pdf注意) Yusteがやってたoptogeneticsのonline meeting質問のシーン KR2の構造解析（N筆頭その２） の新着論文レビュー 神取研 木暮先生 2013年のNature Communicationsの論文 吉澤研 Editorial Notes: なんか一人でベラベラ話していて、聞き直してみると非常に恥ずかしいですね。。穴があったら入りたい気分です。あと、ビタミンD不足で病院のお世話になった時は我ながらビックリしました。構造解析の比重は減らすと言いましたが、普通の構造解析の比重は減らす一方、dynamicsやin situでの構造解析は今後も続ける予定です（加藤） フェイク修論発表→本丸ねーちゃー、太陽の降り注ぐかりふぉーにゃでVitD不足、などなど、ついったー経由で仕入れていた武勇伝に関して突っ込むのを失念しておりやらかしたー (萩原) 思えば分子生物学にハマったのはK+チャネルのイオン選択性フィルターがK+より小さいNa+イオンを透過させない仕組みに感動したのがきっかけでした(宮脇)

Ben Oakes is Co-founder, President, & CEO @ Scribe Therapeutics. He has contributed to over 25 publications and patent applications across synthetic biology, molecular engineering, CRISPR, and zinc finger-based genetic modification. A previous Innovative Genomics Institute Entrepreneurial Fellow, Ben has been named to the San Francisco Business Times 40 Under 40, Endpoints 20 Under 40 in biopharma, Business Insider 30 Under 40 transforming healthcare, and the Biocom Life Sciences Catalyst Awards. He received a PhD in Molecular and Cellular Biology from the University of California, Berkeley, where he worked in the Doudna Lab and Savage Lab developing CRISPR-Cas9 molecules with enhanced characteristics.Dave Savage is Co-founder & Scientific Advisor @ Scribe Therapeutics. He is an Associate Professor of Biochemistry, Biophysics, and Structural Biology at the University of California, Berkeley and in 2021 was selected as an Investigator of the Howard Hughes Medical Institute. Dave is an expert in biochemistry and protein engineering, and his laboratory develops novel tools for studying and manipulating the genome. Previously, he was a Department of Energy Physical Biosciences Fellow of the Life Sciences Research Foundation at Harvard Medical School.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

Ray Stevens, CEO of ShouTi, on structural biology driven drug discovery.

The journey to understanding these critically important molecules, in their thousands of different flavors, began with a chance discovery. Today, after decades of painstaking lab work and dizzying technological leaps, the field of protein science is exploding.

Today's guest is Jasmine Cubuk, a 5th year PhD Candidate in the Biochemistry, Biophysics, and Structural Biology program at WashU. Jasmine currently studies intrinsically disordered proteins. In an attempt to advance research in regards to the current pandemic, Jasmine's lab work is focused on the SARS-CoV-2 Nucleocapsid protein. In this conversation, Jasmine shares tons of information about her introduction to STEM and road completing the PhD. Jasmine believes that science is for everyone, and loves seeing more women in the field. --- Support this podcast: https://podcasters.spotify.com/pod/show/theglamchemist/support

Three new studies shed more light on the Omicron variant of coronavirus suggesting the risk of hospitalisation is lower than with previous variants. But there are still questions to be answered, says James Naismith, Professor of Structural Biology at the University of Oxford, about how quickly it can spread and for how long – something that will have a huge impact on recovering economies. The price of liquified natural gas is spiking around the world to around eight times what it was earlier in the year. Anne-Sophie Corbeau at the Center on Global Energy Policy at Columbia University tells us why, and Nikos Tsafos at the Center for Stretegic and International Studies in Washington, DC, explains how Chinese demand for energy is contributing to rising prices. Apple's investors want to investigate the company's behaviour in China, including allegations of forced labour in the supply chain, and they might just get that: the US financial regulator has blocked Apple's proposals to prevent shareholders from demanding those reports – Patrick McGee of the Financial Times tells us more. The BBC's Elizabeth Hotson looks at the future of high street retail, and in Hong Kong, authorities have removed a statue commemorating the Tiananmen Square massacre under cover of darkness. throughout the programme we're joined by Samson Ellis - Taipei Bureau Chief Bloomberg News and Diane Brady, Assistant Managing Editor of Forbes. Picture: A coronavirus poster on a phone box Credit: Andrew Milligan/PA Wire

In this episode of the Mother Plus Podcast, we cover:When a career change upended Mandy's identity, she used her background in both biochemistry and mindset to create a business supporting the mental health of  prospective medical students who are preparing for the MCAT. Why and how Mandy made a professional pivot during the pandemic. What happens when the right thing for your family isn't the best for your career? Mandy shares her guilt-free perspective and why work makes her a better mom. Honor your motherhood style: why a “one size fits all” approach doesn't work when it comes to parenting choices. Small, incremental steps are the key to success: Be authentic and follow your gut when starting your business-- you do not have to do what everyone else is doing or have everything perfect.Mandy Siglin has a lot of titles: Mother to three + PhD, yoga instructor and mindset coach. Siglin received her PhD in Molecular Pharmacology and Structural Biology from Thomas Jefferson University.  She lovingly served as the Director of Juniata College's Health Professions Program for five years. When family circumstances took her away from her Director position right before the pandemic hit, she had to make a pivot. Inspired by her ability to change the students she worked with in the past with her unique science and mindset perspective, she founded ThiveMed, a company dedicated to the wellbeing of pre-med students. Mandy uses strategic, evidence-based practices to help students increase their confidence and lower their stress and anxiety around standardized entrance exams for admission to professional school. Mandy lives in North Carolina with her husband, Josh, and three children.Where you can find her:Instagram: https://www.instagram.com/thrive.med/LinkedIn: https://www.linkedin.com/in/mandy-siglin-a783955a/

Adam is CEO of Visby Medical (formerly Click Diagnostics), which he founded in 2012 to develop easy-use diagnostic tests. In March 2020, the company pivoted from work on a sexual health test to tackle the coronavirus, and in July received FDA emergency authorization approval for its portable COVID-19 test. He is also an associate professor in the Departments of Structural Biology and Electrical Engineering at Stanford University School of Medicine, with research interests spanning a broad field of molecular imaging. His lab is developing new optical imaging tools with applications to cancer and ophthalmic diseases, such as age-related macular degeneration.

Tuba B. from the University of Ottawa talks to Dr. Joanne Lemieux a Professor of Structural Biology at the University of Alberta in the Faculty of Medicine & Dentistry. Most recently, during the COVID-19 pandemic, as the principal investigator on the study, Dr. Lemieux worked to develop an antiviral drug against coronavirus disease. In this interview, Dr. Lemieux speaks on her discovery of antiviral protease agents that interfere with SARS-CoV-2, the chemical design process of drug development, and her perspective on the future of antiviral pills. Learn more: https://lemieuxlab.biochem.ualberta.ca/ 

You may have heard of Watson and Crick and their breakthrough of The Double Helix (The Structure of DNA) utilizing Sir Lawarence Bragg's X-Ray diffraction methodology in crystallography. There's an architecture in the field of Structural Biology related to DNA that's absolutely fascinating…a breakthrough that scientists such as Perutz, Kendrew, Hodgkin have already pioneered into. But have you heard of R2 RNA? Have you heard of splicing RNA for recodification…that there's an ability to reprint by blueprint a repair of the structure of RNA? In this short expanded episode from the PH10 52. TRANSFIGURATION AD II event listen in as Vickery off the cuff gives a theoretical account of how and possibly why “R2 RNA” was brought out of the encounter Moffitt had. The most immediate proof of the compatibility of religion (qualitative) and natural science (quantitative) under the most thorough critical scrutiny, is the historical fact that the very greatest natural scientists of all times—men such as Kepler, Newton, Leibniz—were permeated by a most profound religious attitude. Max Planck Both religion and science require a belief in God. For believers, God is in the beginning, and for physicists He is at the end of all considerations… To the former He is the foundation, to the latter, the crown of the edifice of every generalized world view. - Scientific Autobiography and Other Papers as translated by F. Gaynor (1949), p. 184 Glorification | The Final Frontier Going Boldly Where The Last Man has Gone Before! Decrease time over target: PayPal.me/mzhop or Venmo @clastronaut

The PodiumRunner Endurance Podcast is hosted by Ian Sharman, a professional ultra runner and coach with over 200 marathons or ultra finishes and more than 50 wins (www.sharmanultra.com, @sharmanian). We discuss training and racing topics with leading sports scientists and how to practically apply research findings for marathoners and ultra runners. Ep. 19: Returning from Injury with Hillary "Hillygoat" Allen  This episode we're talking to Hillary Allen who is an endurance athlete and coach specializing in mountain ultra marathons where she's earned the nickname, "Hillygoat." She started running in 2011 and comes from a background of high-level athletics, playing tennis in college. She's podiumed at many races around the world and is probably best known for her serious injury from a near-fatal fall at a race in Norway in 2017 and the return to racing afterwards, documented in the book, ‘Out and Back: A Runner's Story of Survival Against All Odds.' She also has a Masters in Neuroscience and Physiology and Structural Biology and co-hosts the Trail Society podcast. You can follow Hillary on Twitter (@hillygoatclimbs) and Instagram (@hillygoat_climbs). This show we're talking about returning from injury or a longer break from running. We discuss: Hillary's accident at the Tromsø Skyrace in 2017 and the resulting months. How she focused on physical rehab, despite seemingly minimal gains much of the time. Her mental approach to recovery, including returning to that same race to complete it two years later. What she's learned and useful takeaways for anyone who gets injured.

Vijay Pande is a General Partner @ Andreessen Horowitz (a16z), where he focuses on investments in Biopharma & Healthcare. As the founding investor of a16z's Bio Fund, Vijay leads the firm's investments at the cross section of biology and computer science, including applications in computation, machine learning, and artificial intelligence in healthcare; digital therapeutics; diagnostics; and other novel transformative scientific advances applied to industry that take bio beyond healthcare. Op-eds by Vijay defining trends and issues in this emerging space have been published by The New York Times, Scientific American, and Forbes, among others. He is also an Adjunct Professor of Bioengineering at Stanford University.Previously, Vijay was the Henry Dreyfus Professor of Chemistry and Professor of Structural Biology and of Computer Science at Stanford University, where he led a team of researchers pioneering computational methods and their application to medicine and biology (resulting in over 300 publications, two patents, and two novel drug candidates). Vijay was also concurrently the director of the Biophysics program at Stanford, where he led a team of more than 50 faculty members and propelled the program to the top in the country.During his time at Stanford, Vijay co-founded Globavir Biosciences, where he translated his research advances into a successful startup that aimed to discover cures for Dengue Fever and Ebola. Vijay also founded the Folding@Home Distributed Computing Project for disease research, which pushed the boundaries of computer science techniques (distributed systems, machine learning, and exotic computer architectures) into biology and medicine, in both research as well as the development of new therapeutics.Vijay holds a BA in Physics from Princeton University and a PhD in Physics from MIT. He has been awarded the DeLano Prize in Computation; a Guinness World Record for Folding@Home; the American Chemical Society Thomas Kuhn Paradigm Shift Award; and was selected for MIT TR10. In his teens, Vijay was the first employee at video game startup Naughty Dog Software, maker of Crash Bandicoot.Vijay serves on the board of the following Andreessen Horowitz portfolio companies: Apeel Sciences, BioAge Labs, Ciitizen, Devoted Health, Freenome, Insitro, Nautilus Biotechnology, Omada Health, Scribe Therapeutics, and Q Bio.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

Welcome to a new BioPOD series: Scotland's Biotech Stories. In this installment, BioPodder Liz Gaberdiel interviews Dr. Marcus Wilson on Cryogenic electron microscopy (CryoEM), a  technique that has undergone some serious upgrades since its initial development in the 1960s. Introduction by Neelakshi Varma & Editing by Sam Haynes Media by Hanna Peach and Chris Donohoe 

Now, when it comes to the obesity crisis facing many developed nations all across the world it can be easy to be reductive about it. “Just eat less” or “ just cut out the junk” or something like that. But what if there was something going on inside your brain that meant you never felt satisfied? What if you felt hungry all the time no matter how much you ate? How could we fight such a primal urge? Dr Moran Shalev-Benami, from the Department of Chemical & Structural Biology & Principal Investigator at the Weizmann Institute of Science in Israel joined Jonathan to discuss

Pod of Jake Podcast Notes Key Takeaways Biology is the science we need today: the trend is moving from physics to biology Machine learning is going to have a strong impression on pharmaceuticals, computer diagnostic tools, and healthcare as a wholeEducation, as it stands, is not scalable – if we can get the right structure and balance between absorbing information and network, education as we know it will change Two possible directions of San Francisco tech: (1) Scale the Bay – mix in-person and virtual work which will allow for collaboration and creativity but ease traffic; (2) Remain virtual and create distributed companies in the future but work to harness the spirit of San Francisco culture and big thinking “There's more to life than being efficient…working from home sounds good but too often I think you're really living at work.” – Vijay PandeTransitioning to remote work and lifestyle is a matter of “when” not “if” The cost of healthcare in the U.S. is rising to unsustainable levels and becoming a crisis Important to study older people and understand elements of what allows people to live longer and age slower versus contract diseaseThinking about reversing aging, longevity, and healthspan is now part of basic science Read the full notes @ podcastnotes.orgVijay is a general partner at Andreessen Horowitz, where he focuses on investments in biopharma and healthcare. As the founding investor of a16z's Bio Fund, he leads the firm's investments at the cross section of biology and computer science. Previously, Vijay was the Henry Dreyfus Professor of Chemistry and Professor of Structural Biology and of Computer Science at Stanford University. During his time at Stanford, Vijay co-founded Globavir Biosciences and the Folding@Home Distributed Computing Project for disease research. Vijay remains an Adjunct Professor of Bioengineering at Stanford University and holds a BA in Physics from Princeton University and a PhD in Physics from MIT. Disclaimer: a16z investments are discussed in this conversation. None of the content should be taken as investment advice. See a16z.com/disclosures for more information. [0:59] - How Vijay ended up at the intersection of biology and technology [6:15] - The academic shift from physics towards biology [12:32] - The difficulty of scaling education [16:38] - Vijay's predictions for the future of work and The San Francisco Bay Area [26:31] - Using distributed computing to simulate protein folding with Fold@Home [38:19] - The rising cost of healthcare and where the industry is moving [49:46] - Targeting longevity as a solution to harmful diseases --- homeofjake.com

Vijay is a general partner at Andreessen Horowitz, where he focuses on investments in biopharma and healthcare. As the founding investor of a16z’s Bio Fund, he leads the firm’s investments at the cross section of biology and computer science. Previously, Vijay was the Henry Dreyfus Professor of Chemistry and Professor of Structural Biology and of Computer Science at Stanford University. During his time at Stanford, Vijay co-founded Globavir Biosciences and the Folding@Home Distributed Computing Project for disease research. Vijay remains an Adjunct Professor of Bioengineering at Stanford University and holds a BA in Physics from Princeton University and a PhD in Physics from MIT. Disclaimer: a16z investments are discussed in this conversation. None of the content should be taken as investment advice. See a16z.com/disclosures for more information. [0:59] - How Vijay ended up at the intersection of biology and technology [6:15] - The academic shift from physics towards biology [12:32] - The difficulty of scaling education [16:38] - Vijay's predictions for the future of work and The San Francisco Bay Area [26:31] - Using distributed computing to simulate protein folding with Fold@Home [38:19] - The rising cost of healthcare and where the industry is moving [49:46] - Targeting longevity as a solution to harmful diseases --- homeofjake.com

In today’s Metabolic Moment, Dr. Power explains what structural biology is and how it is helpful in determining the effects, fates, and interactions of molecules. By determining the shape of a virus, drug makers will be able to craft very specific treatments, so it is an important and exciting specialty in the life sciences! Tune in today to learn more.

In this episode, I speak with Prof. Mohammed AlQuraishi. Mohammed is an Assistant Professor in the Department of Systems Biology at Columbia University. Mohammed gives us his unique thoughts and perspectives on a variety of problems that lie at the intersection of machine learning and structural biology.   (00:30) -- vision of Mohammed's lab (02:45) -- importance of abstractions to simulate a cell (04:29) -- conceptual advances in abstractions (06:03) -- protein folding (07:28) -- end-to-end differentiability (10:12) -- representations learned by protein structure deep learning models (14:07) -- predicting higher energy states in conformational space (15:46) -- is structure overrated? (18:10) -- protein localization prediction (20:37) -- pitfalls of having a programmatic view of a cell (23:34) -- why individuals with quantitative backgrounds may find biology interesting

Since the elucidation of the DNA structure by James Watson and Francis Crick in 1951, the importance of understanding the three-dimensional structure of biomolecules has become obvious. Over the last few decades scientists have resolved the structure of thousands of complex biomolecules enabling incredible innovations in drug design, biological and medical sciences. X-Ray crystallography has been the key technique, but in recent years Nuclear Magnetic Resonance (NMR) has emerged as an additional, complementary approach. Dr. Loren Andreas explains to us how NMR has grown to be the technology of choice as it has expanded its field of application from liquid solutions to condensed systems. The discussion is a surprising discovery of how progress in engineering and instrument design has completely changed the landscape in structural biology. Modern NMR allows scientists to study molecules in complex systems, simulating more closely their natural environment, including interaction between them. This episode offers an exciting glimpse of the future, through a few examples from today’s science.Visit https://thermofisher.com/bctl to register for your free Bringing Chemistry to Life T-shirt and https://www.alfa.com/en/chemistry-podcasts/ to access our episode summary sheet, which contains links to recent publications and additional content recommendations for our guest.

In which Vaibhav speaks with Dr. Mohammed AlQuraishi, an Assistant Professor of Systems Biology at the Columbia University Irving Medical Center, about using machine learning to predict protein structure. Among other things, they discuss the direction of algorithmic development in computational structure prediction, from neighborhood-based assembly of peptide fragments to modern applications of Deep Learning in structural modeling. They discuss the features of physical priors and discuss approaches in computationally optimizing protein-energy state predictions, taking into account the difficulties associated with the many local minima in an energy function. Throughout this discussion, Mohammed contextualizes the intuition behind the methods used by Deep Mind with their developments of AlphaFold.

Eric Rubin is the Editor-in-Chief of the Journal. Lindsey Baden is a Deputy Editor of the Journal. Jonathan Abraham is a structural biologist in the Department of Microbiology at Harvard Medical School and an infectious disease physician at Brigham and Women’s Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin and Others. Audio Interview: The Implications of Changes in the Structural Biology of SARS-CoV-2. N Engl J Med 2021;384:e48.

Zu Weihnachten haben wir uns nochmal richtig bemüht und unseren ersten Gast eingeladen: Dr. Janina Sprenger ist Wissenschaftlerin am Deutschem Elektronen-Synchrotron "DESY". Sie ist auf Protein Kristallographie spezialisiert, was bedeutet, dass sie mithilfe von Röntgenstrahlung Biomoleküle "sichtbar" macht und analysiert. Diese Erkenntnisse können dann für Medikamente benutzt werden, zum Beispiel forscht sie gerade mit an möglichen Gegenmitteln für Corona. Wir haben ihr zahlreiche Fragen gestellt: Unteranderem über ihre Forschung, über ihre Doktorarbeit in Schweden und wie man als Wissenschaflter:in in der Gesellschaft wahrgenommen wird. Inhaltsverzeichnis 0:41 Vorstellung 2:12 Forschung am Desy bezüglich Covid 3:32 Was ist überhaupt Kristallographie 6:39 Doktorarbeit in Schweden, Ihre Forschung an Malaria 15:56 Wie sieht ein Tag als Protein Kristallograph:in aus? 19:35 Klischees über Wissenschaftler:innen 24:28 Rosalind Franklin & Frauen in der Wissenschaft 31:37 Was bedeutet künstliche Intelligenz für Kristallographie? Wird "Alpha Fold" ihre Arbeit unwichtig machen? 41:02 Schlusswort Links: Sprenger, Janina. (2014). hree-dimensional structures of Plasmodium falciparum spermidine synthase with bound inhibitors suggest new strategies for drug design. Acta Crystallographica Section D Biological Crystallography. Sprenger, Janina. (2020). Structural Biology of Pf AdoMetDC - Challenges in Crystallizing a Malarial Protein. https://www.youtube.com/watch?v=o25Nda3OHcM&feature=emb_logo https://en.wikipedia.org/wiki/Drug_discovery http://www.scienceandsociety.eu/2017/06/30/young-scientists-interview-with-janina-sprenger/

In his second presentation, Haas shares an example of how cryocrystallography has aided structure-based drug design.

In his second presentation, Haas shares an example of how cryocrystallography has aided structure-based drug design.

Dr. Vivian Chan is the founder and CEO of Sparrho, a platform that democratizes science using augmented intelligence. Dr. Chan has a PhD in biochemistry, and degrees in biotech. She has addressed the EU Ministers of Research and Innovation and keynoted the "Next Unicorn" series at Mobile World Congress.Episode NotesMusic used in the podcast: Higher Up, Silverman Sound StudioWere there fines in UK for leaving lock down in early COVID? Are there now? Under current regulations, organisers and facilitators of large gatherings (more than six) can be fined up to £10,000.Brits who do not wear a face covering in places where it is mandatory, such as in shops, supermarkets and on public transport, could be issued with a fine. Police can also break up any gatherings larger than six and can issue a £200 fine if they do not comply. Sparrho - www.sparrho.comB to B to C - It's the very definition of the oft-cited CPG industry “b-to-b-to-c” (b2b2c) model, where the supplier sells its products to retailers, who in turn sell to consumers. ... Many CPGs are today claiming a new focus on consumer centricity; that it's their consumer who matters, who they care about, and who they serve. (www.briansolis.com) B to B - Business-to-business, is a process for selling products or services to other businesses. Biotechnology - a broad area of biology, involving the use of living systems and organisms to develop or make products. (wikipedia)Biochemistry - the branch of science concerned with the chemical and physicochemical processes and substances that occur within living organisms. (wikipedia)Maths C covers additional pure-maths topics (including complex numbers, matrices, vectors, further calculus and number theory). Maths C gives the students an understanding of the methods and principles of mathematics and the ability to apply them in everyday situations and in purely mathematical contexts; the capacity to model actual situations and deduce properties from the model. (wikipedia)Structural Biology - a branch of molecular biology, biochemistry, and biophysics concerned with the molecular structure of biological macromolecules (especially proteins, made up of amino acids, RNA or DNA, made up of nucleotides, membranes, made up of lipids) how they acquire the structures they have, and how alterations in their structures affect their function. (wikipedia)RNA - ribonucleic acid, a nucleic acid present in all living cells. Its principal role is to act as a messenger carrying instructions from DNA for controlling the synthesis of proteins, although in some viruses RNA rather than DNA carries the genetic information. X-ray crystallography - the study of crystals and their structure by means of X-ray diffraction.Homeostasis - the tendency toward a relatively stable equilibrium between interdependent elements, especially as maintained by physiological processes.Ligand - is an ion or molecule (functional group) that binds to a central metal atom to form a coordination complex. The bonding with the metal generally involves formal donation of one or more of the ligand's electron pairs.

In this episode, I talk to Dr Onisha Patel, who is a structural biologist at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, Australia I speak to her about: – How she got into science from her interest in art – What inspired her growing up – Structural Biology and what […]

In this episode, your hosts, Dr. Sabah Kadri and Arshi Arora bring to you united yet diverse sub fields of Computational Biology in the voice of four different scientists, spanning areas of Structural Biology, Systems Biology, Chemistry, Proteomics and Genomics. They cover their background, speciality and what drew them to Computational ability in the first place. Contact us with questions, feedback and requests to collaborate on future episodes at computationallyyours@gmail.com. Follow us on Twitter: @compbiopodcast ; Dr. Sabah Kadri: @sabahkadri ; Arshi Arora: @arorarshi Website: http://computationallyyours.netlify.app/ Follow us on Instagram https://www.instagram.com/computationallyours/ Intro/Outro music: Riatsu (Shadaab Kadri) Thumbnail: Thanks to Zoltan Tasi for sharing their work on Unsplash. --- Send in a voice message: https://anchor.fm/computationally-yours/message

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.24.265553v1?rss=1 Authors: Currell, F., Villagomez Bernabe, B., Chan, S.-w., Roseman, A., Coulter, J. Abstract: Here we show an interplay between the structures present in ionization tracks and nucleocapsid RNA structural biology, using fast ion beam inactivation of the severe acute respiratory syndrome coronavirus (SARS-CoV) virion as an example. This interplay is one of the key factors in predicting dose-inactivation curves for high energy ion beam inactivation of virions. We also investigate the adaptation of well-established cross-section data derived from radiation interactions with water to the interactions involving the components of a virion, going beyond the density-scaling approximation developed previously. We conclude that solving one of the grand challenges of structural biology - the determination of RNA tertiary/quaternary structure structure - is intimately linked to predicting ion-beam inactivation of viruses and that the two problems can be mutually informative. Indeed, our simulations show that fast ion beams have a key role to play in elucidating RNA tertiary/quaternary structure. Copy rights belong to original authors. Visit the link for more info

BROADCAST YOURSELF - 8 Week Course: https://londonreal.tv/by/ 2021 SUMMIT TICKETS: https://londonreal.tv/summit/ NEW MASTERCLASS EACH WEEK: http://londonreal.tv/masterclass-yt LATEST EPISODE: https://londonreal.link/latest Professor Michael Levitt is a Nobel Prize-winning biophysicist who has conducted pioneering work on the molecular structure of essential biological compounds. He has made many significant contributions to the study of protein folding and helped to popularise the use of computer modelling in biology. Amongst the foremost of Michael’s numerous scientific achievements is his development of the first computerised model of an enzyme reaction, which was subsequently expanded to simulate more generalised protein dynamics. He has also carried out important research on the modelling of antibodies as well as DNA and messenger RNA — work that has informed practical advances in biomedical science. Michael has received many honours and awards for his research, including the 2013 Nobel Prize in Chemistry and the 2014 DeLano Award for Computational Biosciences. A member of the US National Academy of Sciences, since 1987 he has been a Professor of Structural Biology at Stanford University.

Join Kash as he interviews scientist Heidar Koning on his research into structural biology, DNA and RNA, CRISPR and much more!   

On March 11, 2020, people all over the world were thrust into a new reality when the coronavirus was declared a global pandemic. It was as if the globe had ground to a halt as businesses closed, schools shuttered, and stay-at-home orders emptied city streets. Thousands of lives have been lost; all lives have been changed.  Over the past two months, despite these uncertain and unprecedented circumstances, there have been shining examples of goodness and triumphs of the human spirit solidifying the fact that we as a species are both adaptable and resilient. Scientists around the globe have aligned their focus to find solutions to this challenge of historic proportions, and groundbreaking discoveries have been made. Everyday, we continue to make progress in quelling the impact of this virus and protecting our loved ones at risk.  Unfortunately, much of the COVID-19 news comes to us clouded by the business of mass media which built momentum selling us a narrative of fear.  In this episode, Tony goes on a journey to uncover the truth about coronavirus with a 7-person panel of highly qualified researchers, an experienced epidemiologist, a Nobel Laureate, and M.D.s testing and treating patients on the frontlines. Together, they reveal the evidence-based research that has come to light and the emerging facts that you’re not hearing in the headlines that are absolutely crucial in shaping decisions about how to move forward.  This is one of the most important interviews that Tony has conducted in his 40+ year career. It reminds us to stand guard at the door of our mind, practice discernment when determining trustworthy sources, and think critically for ourselves in order to stay flexible and maintain the ability to pivot in light of new information – especially when lives depend on it.  Podcast panelists in this episode include:  Dr. Michael Levitt, PhD, Nobel Prize – Chemistry; Professor of Structural Biology, Stanford University  Dr. Eran Bendavid, M.D., Associate Professor of Medicine, Stanford University  Dr. Michael Roizen, M.D., Chief Wellness Officer Emeritus, Cleveland Clinic Dr. Alan Preston, Sc.D, Former Professor of Epidemiology & Biostatistics, Texas A&M University Senator Scott Jensen, M.D., Family Physician; Senator (R-Minnesota)  Dr. Dan Erickson, M.D., Co-Owner, Accelerated Urgent Care Dr. Artin Massihi, M.D., Co-Owner, Accelerated Urgent Care EPISODE NOTES: [00:00:00] Introduction from Tony Robbins [00:08:30] Interview with Dr. Michael Levitt [00:27:00] Interview with Senator Scott Jensen, M.D. [00:39:00] Interview with Dr. Eran Bendavid, M.D [00:49:30] Interview with Dr. Alan Preston, Sc.D [01:17:30] Interview with Dr. Michael Roizen, M.D. [01:38:00] Interview with Dr. Dan Erickson, M.D. [01:45:30] Interview with Dr. Artin Massihi, M.D. [01:55:25] Round-Robin discussion [02:34:20] Tony’s closing comments

If the best way to know whether a medicine is effective is through a clinical trial, then where does (and doesn't) real-world data and real-world evidence come in? The topic is always top of mind in drug development, with additional focus as of 2016 thanks to the 21st Century Cures Act -- but is especially heated lately given recent concerns and claims around particular drugs in the context of the novel coronavirus pandemic.So in this short-but-deep dive episode of 16 Minutes on the News, a16z general partner in bio Vijay Pande -- previously a professor of Chemistry, Structural Biology, and Computer Science at Stanford University (as well as founder of Folding@Home) -- breaks down the debate between RWE vs. RCT (real world evidence and randomized controlled trials), in conversation with Sonal Chokshi. Is it a tradeoff between speed of innovation and safety, or is it a false dichotomy altogether? Where do and don't statistics come in when it comes to policy? How has, and could, the role of the FDA (as well as payers reimbursing healthcare) evolve here? And where can technology help?

Dr. Lisa Eshun-Wilson has a Ph.D. in Molecular and Structural Biology from UC Berkeley. She is the first African-American to graduate within her field of study from UC Berkeley. Even more interesting, in the summer of 2019 - Lisa went to a conference in her field in China, and out of thousands of applications, Lisa was the ONLY African American to apply. She is an advocate to increase the number of diverse students in this field, and make sure there is mentorship available as students navigate through undergrad and grad school. Tune in and learn more about her story!Support the show (https://www.gofundme.com/manage/stem-communications-fund)

Now a professor of biochemistry at the University of Cambridge, in 1969 Sir Thomas Blundell was one of the first people to see what the hormone insulin looked like. As part of the team led by Nobel Prize winner Dorothy Hodgkin, it was a medical breakthrough for diabetes patients everywhere. “I was always interested in doing a range of different things,” Professor Blundell says. “I came from a family where my grandfather was a very gifted artist and musician. And although my parents left school when they were 14 and 15, they always encouraged me to think more broadly.” “So I may be a little bit unusual because I’ve ended up doing things in politics, music and science, and that of course led me to advise prime ministers and to run organisations and found companies.” Professor Blundell’s research has focussed on understanding the structure and function of molecules for targets to improve drug design. “By using X-rays with very short wavelength, I can see these very tiny molecules. Add in other methods like electron microscopy and the individual molecules can be revealed. His work has contributed significantly to stopping the progression of HIV into AIDS and to developing new drugs for cancer treatment in both his academic career and through a spinoff company he initially founded with two former students. “In Europe, Australia and the United States, we are lucky, we have access to medicines that research has developed, but the real challenge is to make sure that it’s available not just to the rich, but to the world in general.” Episode recorded: September 26, 2019. Interviewer: Dr Andi Horvath. Producer, audio engineer and editor: Chris Hatzis. Co-production: Silvi Vann-Wall and Dr Andi Horvath. Image: Getty Images.

Nobel Prize-winning structural biologist, Knight Bachelor, President of the Royal Society, brilliant structural biologist and enthralling author Venki Ramakrishnan tells the story of his race to discover the inner workings of biology's most important molecule - the ribosome, in this articulate, witty and surprisingly philosophical series of videos.

Krishna starts a new format for the podcast, and talks about how the field of structural biology has dramatically changed in the past 5 years.

Professor Eva Nogales started her career in a time where barely any women were seen in science departments. In college, she skipped biology to focus on physics, relying on her high-school knowledge of the former to shape her career as a biophysicist. Now, she’s using her understanding of the microtubules in our cells for improving disease management, including slowing the uncontrollable growth of cancer. This niche understanding of our cell behaviour at the molecular level is already improving the lives of humans everywhere, and the technique used by Professor Nogales called “cryo-EM” is taking the world of structural biology by storm. She recently visited the University of Melbourne to receive the 2019 Grimwade Medal, and to deliver the oration titled: Visualising the molecular dance at the heart of human gene expression. Episode recorded: February 14, 2019.Interviewer: Steve Grimwade.Producer and editor: Chris Hatzis.Co-production: Silvi Vann-Wall and Dr Andi Horvath.Banner: Berkeley Lab.

The 2019 Haldane Lecture was delivered by Sir Venki Ramakrishnan, President of the Royal Society, on February 7th at Wolfson College, Oxford. The lecture was introduced by College President Sir Tim Hitchens. The thousands of genes in our DNA are translated by ribosomes - ancient, enormous molecular machines that read the genetic code to make the thousands of proteins that carry out the functions of life. Although the ribosome was discovered in the 1950s, unravelling its million atom structure took over four decades. Venki Ramakrishnan will frame this in term of his career and show how science does not proceed in a series of logical steps but in fits and starts, with many characters and their egos, rivalries, competition and collaboration, blunders and dead ends. Sir Venki is a structural biologist who in 2009 received the Nobel Prize in Chemistry and was knighted in 2012. In 2015, he was elected as President of the Royal Society.

Erica Ollmann Saphire discusses her research on Ebola virus glycoprotein and the changing nature of structural biology. The Ebola virus glycoprotein sequence can vary up to 50% between Ebola virus species, presenting a challenge to develop pan-Ebola therapeutics or vaccines. Erica Ollmann Saphire discusses her work on antibodies that neutralize all Ebola virus species and the changing nature of the structural biology toolkit used to study them. Check out all our great podcasts at asm.org/podcast MTM Listener Survey: asm.org/mtmpoll Ollmann-Saphire Lab Site Protein Database Isolation of Potent Neutralizing Antibodies from a Survivor of the 2014 Ebola Virus Outbreak. Science 2016. Systemic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Proteciton. Cell 2018. Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope. mBio 2018. Tenacious Researchers Identify a Weakness in All Ebolaviruses. mBio 2018. HOM Tidbit: How “Lassa,” a small Nigerian Town, was Stigmatized by having a Killer Virus Named after it.

11 września 2018 roku Rada Wydziału Biologii i Ochrony Środowiska UŁ podpisała porozumienie o współpracy oraz nadała tytuł honorowego pracownika naukowego UŁ Prof. Russelowi Reiterowi z University of Texas Health Science Center Department of Cellular & Structural Biology w Stanach Zjednoczonych. Uroczystości tej towarzyszył wykład prof. Russela Reitera “Success in Science: Requirements and Expectations”.

Melvyn Bragg and guests discuss enzymes, the proteins that control the speed of chemical reactions in living organisms. Without enzymes, these reactions would take place too slowly to keep organisms alive: with their actions as catalysts, changes which might otherwise take millions of years can happen hundreds of times a second. Some enzymes break down large molecules into smaller ones, like the ones in human intestines, while others use small molecules to build up larger, complex ones, such as those that make DNA. Enzymes also help keep cell growth under control, by regulating the time for cells to live and their time to die, and provide a way for cells to communicate with each other. With Nigel Richards Professor of Biological Chemistry at Cardiff University Sarah Barry Lecturer in Chemical Biology at King's College London And Jim Naismith Director of the Research Complex at Harwell Bishop Wardlaw Professor of Chemical Biology at the University of St Andrews Professor of Structural Biology at the University of Oxford Producer: Simon Tillotson.

Melvyn Bragg and guests discuss enzymes, the proteins that control the speed of chemical reactions in living organisms. Without enzymes, these reactions would take place too slowly to keep organisms alive: with their actions as catalysts, changes which might otherwise take millions of years can happen hundreds of times a second. Some enzymes break down large molecules into smaller ones, like the ones in human intestines, while others use small molecules to build up larger, complex ones, such as those that make DNA. Enzymes also help keep cell growth under control, by regulating the time for cells to live and their time to die, and provide a way for cells to communicate with each other. With Nigel Richards Professor of Biological Chemistry at Cardiff University Sarah Barry Lecturer in Chemical Biology at King's College London And Jim Naismith Director of the Research Complex at Harwell Bishop Wardlaw Professor of Chemical Biology at the University of St Andrews Professor of Structural Biology at the University of Oxford Producer: Simon Tillotson.

Thursday, August 25, 2016 Jim Lechleiter (Cellular & Structural Biology, UTHSCSA) gets us up to speed on astrocytes, their role in brain health and homeostasis, and their properties as excitable cells. Duration: 50 minutes Discussants:(in alphabetical order) Michael Beckstead (Assoc. Prof, UTHSCSA) Carlos Paladini (Assoc. Prof, UTSA) Salma Quraishi (Res. Asst Prof, UTSA) Matt Wanat (Asst Prof, UTSA) Charles Wilson (Ewing Halsell Chair, UTSA) acknowledgement: JM Tepper for original music.

Jim Lechleiter (Cellular & Structural Biology, UTHSCSA) gets us up to speed on astrocytes, their role in brain health and homeostasis, and their properties as excitable cells. Duration: 50 minutesDiscussants:(in alphabetical order)Michael Beckstead (Assoc. Prof, UTHSCSA)Carlos Paladini (Assoc. Prof, UTSA)Salma Quraishi (Res. Asst Prof, UTSA)Matt Wanat (Asst Prof, UTSA)Charles Wilson (Ewing Halsell Chair, UTSA) acknowledgement: JM Tepper for original music.

This is a great episode-- I had a chance to chat with Hillary Allen, a teacher in Neuroscience and Structural Biology who also happens to be a professional athlete on the ultrarunning team for The North Face. Hillary brings some valuable insight into achieving work-life balance and pushing her limits both mentally and physically. In an industry that is heavily guided by the pursuit of passion, there are some great takeaways for you about making time to achieve the goals that are most important to you and being a well-rounded human being outside of athletics.

Structure of viruses Professor David Stuart studies the structure of viruses at the molecular level. His work is particularly interested in virus-receptor interaction and the basic puzzles of virus assembly and he uses structural biology to answer these questions.

Understanding the function of a protein is an important step in finding out why the body succumbs to disease – but how do scientists find these proteins and figure out how they work?

Dr. Joel Levine is an Associate Professor of Biology and the Canada Research Chair in Neurogenetics at the University of Toronto, Mississauga. He received his PhD in Dr. Richard Miselis Anatomy and Structural Biology from the University of Pennsylvania. He then completed a Postdoctoral Fellowship with Rob Jackson at the Worcester Foundation for Biological Research, a postdoc fellowship with Dr. Steven Reppert at Harvard University, and a postdoc with Dr. Jeffrey Hall at Brandeis University before joining the faculty at the University of Toronto. Joel is here with us today to tell us all about his journey through life and science.

Structure of viruses Professor David Stuart studies the structure of viruses at the molecular level. His work is particularly interested in virus-receptor interaction and the basic puzzles of virus assembly and he uses structural biology to answer these questions.

Dr. Stephen Curry is a Professor of Structural Biology and Director of Undergraduate Studies in the Department of Life Sciences at Imperial College London. He received his PhD from Imperial College London. Stephen is a Fellow of the Society of Biology and was recently awarded the Peter Wildy Prize for Microbiology Education from the Society for General Microbiology. Stephen is here with us today to tell us all about his journey through life and science.

Dr. James Berger is a Professor in the Department of Biophysics and Biopysical Chemistry at the Johns Hopkins University School of Medicine. He received his PhD in Biochemistry and Structural Biology from Harvard University in 1995. Afterwards he was an independent research fellow at the Whitehead Institute of MIT until 1998. James then joined the faculty at UC Berkeley, where he remained for 15 years until coming to Johns Hopkins University in 2013. James has received many awards and honors during his career, including the National Academy of Sciences Award in Molecular Biology, the American Chemical Society Pfizer Award in Enzyme Chemistry, the American Society for Biochemistry and Molecular Biology Schering-Plough Scientific Achievement Award, a Packard Fellows award, and election to both the American Academy of Arts and sciences and the National Academy of Sciences.

Professor Yvonne Jones tells us how structural biology was brought into the field of immunology in Oxford, at the Wellcome Trust Centre for Human Genetics. Professor Jones also explains the developments of her current research on cell surface receptors as mediators of nerve cells guidance.

Diomedes Logothetis and Rahul Mahajan explain how G proteins activate a potassium channel to slow heart rate.

Meet our Division of Structural Biology. The Division of Structural Biology (STRUBI) is part of the Nuffield Department of Clinical Medicine (NDM) at the University of Oxford. STRUBI is also part of the Wellcome Trust Centre for Human Genetics. The Division includes the Oxford Protein Production Facility (OPPF) and the Oxford Particle Imaging Centre (OPIC).

Structural analysis reveals how a Wnt binds to its receptor.

When a young Mary Jane Osborn announced she wanted to be a nurse when she grew up, her father wondered aloud why she shouldn't be a doctor instead. Fueled by his faith that she could succeed in what was then a man's profession, Osborn went on to study physiology and biochemistry. Her work as a graduate student revealed how methotrexate, now a major cancer drug, acts on the body. Osborn then turned her abilities to microbiology, and spent decades exploring how bacteria make lipopolysaccharides-substances that help give potentially deadly bacteria their toxicity and virulence. Osborn is a professor in the Molecular, Microbial and Structural Biology department at the University of Connecticut Health Center. She was elected to the National Academy of Sciences in 1978.

Professor Yvonne Jones talks about cell-cell communication and how this can help us develop new drugs. Prof. Yvonne Jones is director of the Cancer Research UK Receptor Structure Research Group. Her research focuses on the structural biology of cell surface recognition and signalling complexes. Receptors embedded in the surface are potential targets for therapeutic intervention in many diseases including cancer.

Professor Yvonne Jones talks about cell-cell communication and how this can help us develop new drugs. Cells communicate through receptors on their surface; however, when these finely tuned systems don't work correctly, diseases can be triggered. Professor Yvonne Jones has been working to identify the structural biology of cell surface recognition and signalling complexes. Receptors embedded in the surface are potential targets for therapeutic intervention in many diseases including cancer. Professor Jones is director of the Cancer Research UK Receptor Structure Research Group.

Professor Yvonne Jones talks about cell-cell communication and how this can help us develop new drugs. Cells communicate through receptors on their surface; however, when these finely tuned systems don't work correctly, diseases can be triggered. Professor Yvonne Jones has been working to identify the structural biology of cell surface recognition and signalling complexes. Receptors embedded in the surface are potential targets for therapeutic intervention in many diseases including cancer. Professor Jones is director of the Cancer Research UK Receptor Structure Research Group.

Professor Yvonne Jones talks about cell-cell communication and how this can help us develop new drugs. Prof. Yvonne Jones is director of the Cancer Research UK Receptor Structure Research Group. Her research focuses on the structural biology of cell surface recognition and signalling complexes. Receptors embedded in the surface are potential targets for therapeutic intervention in many diseases including cancer.

Structural analysis reveals how increasing concentrations of monomeric actin prevent a transcriptional coactivator from promoting expression of target genes.

Brain Day 2011 is sponsored by the Neurological Foundation of NZ and the University of Otago. As part of Brain Awareness Week, we join this major international effort to communicate the wonders and achievements of brain research. Dr Louise Parr-Brownlie, from the Department of Anatomy and Structural Biology, speaks on “Shedding light on Parkinson’s Disease” Held March 19, 2011.

Audio PodcastAired date: 4/20/2011 3:00:00 PM Eastern Time

Video PodcastAired date: 4/20/2011 3:00:00 PM Eastern Time

Professor Chas Bountra explains how new drugs can offer novel treatments for neurodegenerative and gastrointestinal diseases, as well as pain disorders. Professor Chas Bountra is interested in identifying and validating target proteins for drug discovery. Various technologies and strategies have allowed him to progress promising clinical candidates into Phase I, II, III studies, and to market. Drug candidates are first selected by screening compounds capable of binding to a target protein. Those compounds are then tested in various assay systems, healthy volunteers and finally in patients. Academic research excels at defining good target proteins. Pharmaceutical companies then facilitate the transition from basic research to clinical trials, producing new therapies for patients.

Professor Chas Bountra explains how new drugs can offer novel treatments for neurodegenerative and gastrointestinal diseases, as well as pain disorders. Professor Chas Bountra is interested in identifying and validating target proteins for drug discovery. Various technologies and strategies have allowed him to progress promising clinical candidates into Phase I, II, III studies, and to market. Drug candidates are first selected by screening compounds capable of binding to a target protein. Those compounds are then tested in various assay systems, healthy volunteers and finally in patients. Academic research excels at defining good target proteins. Pharmaceutical companies then facilitate the transition from basic research to clinical trials, producing new therapies for patients.

Professor Chas Bountra explains how new drugs can offer novel treatments for neurodegenerative and gastrointestinal diseases, as well as pain disorders. Professor Chas Bountra is interested in identifying and validating target proteins for drug discovery. Various technologies and strategies have allowed him to progress promising clinical candidates into Phase I, II, III studies, and to market. Drug candidates are first selected by screening compounds capable of binding to a target protein. Those compounds are then tested in various assay systems, healthy volunteers and finally in patients. Academic research excels at defining good target proteins. Pharmaceutical companies then facilitate the transition from basic research to clinical trials, producing new therapies for patients.

Peter Parham, Professor in the Departments of Structural Biology and Microbiology & Immunology at the Stanford University School of Medicine, explores proteins of the human immune system that vary greatly between individuals and populations which modulate the immune response to infection and cancer, and also influence the success of reproduction and therapeutic transplantation of cells, tissues and organs. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Science] [Show ID: 18704]

Peter Parham, Professor in the Departments of Structural Biology and Microbiology & Immunology at the Stanford University School of Medicine, explores proteins of the human immune system that vary greatly between individuals and populations which modulate the immune response to infection and cancer, and also influence the success of reproduction and therapeutic transplantation of cells, tissues and organs. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Science] [Show ID: 18704]

An interview with Dr John Reynolds, Department of Anatomy and Structural Biology.